Chinese Biotech Firm HJ Science Tumbles in Hong Kong Trading Debut Amid Stiff Competition

Dow Jones13:27

By Jason Chau

Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry.

Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering.

The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet.

According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged that some of the competing products possess significant competitive strengths and advantages over its own offerings.

Still, overall market sentiment around China's biopharma sector remains strong, supported by breakthroughs in advanced drug development, rapid rollouts of innovative therapies, and a wave of licensing deals with global pharmaceutical giants.

Write to Jason Chau at jason.chau@wsj.com

(END) Dow Jones Newswires

June 23, 2026 01:27 ET (05:27 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645959000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 13:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645959000","market":"hk","top_or_hot":-1,"title":"Chinese Biotech Firm HJ Science Tumbles in Hong Kong Trading Debut Amid Stiff Competition","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Jason Chau \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry. \n</p>\n<p>\n  Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering. \n</p>\n<p>\n  The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet. \n</p>\n<p>\n  According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged that some of the competing products possess significant competitive strengths and advantages over its own offerings. \n</p>\n<p>\n  Still, overall market sentiment around China's biopharma sector remains strong, supported by breakthroughs in advanced drug development, rapid rollouts of innovative therapies, and a wave of licensing deals with global pharmaceutical giants. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Jason Chau at jason.chau@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 01:27 ET (05:27 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Biotech Firm HJ Science Tumbles in Hong Kong Trading Debut Amid Stiff Competition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Biotech Firm HJ Science Tumbles in Hong Kong Trading Debut Amid Stiff Competition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-23 13:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Jason Chau \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry. \n</p>\n<p>\n  Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering. \n</p>\n<p>\n  The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet. \n</p>\n<p>\n  According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged that some of the competing products possess significant competitive strengths and advantages over its own offerings. \n</p>\n<p>\n  Still, overall market sentiment around China's biopharma sector remains strong, supported by breakthroughs in advanced drug development, rapid rollouts of innovative therapies, and a wave of licensing deals with global pharmaceutical giants. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Jason Chau at jason.chau@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 01:27 ET (05:27 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645959000","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645959000","pubTimestamp":1782192420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry.Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering.The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet.According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged tha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","06132":"华健未来-B","BK4588":"碎股"},"translate_title":"中国生物技术公司HJ Science在香港首次交易中因激烈竞争而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06132":0.9,"XBI":1.5},"content_text":"By Jason Chau \n\n\n \n\n\n  Shares of Chinese biotech firm HJ Science fell sharply on Tuesday as investors weighed its growth prospects against stiff competition in China's highly competitive pharmaceutical industry. \n\n\n  Its stock declined as much as 48% in the Tuesday morning session, after raising 1.11 billion Hong Kong dollars, equivalent to US$141.6 million, in its Hong Kong initial public offering. \n\n\n  The company, based in the Southwestern city of Chengdu, specializes in developing innovative, small-molecule treatments for autoimmune, metabolic and oncological diseases. Despite already developing three innovative drugs as well as six other candidates in the pipeline, none have received approval for commercialization yet. \n\n\n  According to its exchange filing, HJ Science faces potential competition from a wide range of drugmakers working on treatments that overlap with the indications and target patient populations of its own drug candidates, including from major global pharmaceutical companies. The company acknowledged that some of the competing products possess significant competitive strengths and advantages over its own offerings. \n\n\n  Still, overall market sentiment around China's biopharma sector remains strong, supported by breakthroughs in advanced drug development, rapid rollouts of innovative therapies, and a wave of licensing deals with global pharmaceutical giants. \n\n\n \n\n\n  Write to Jason Chau at jason.chau@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2026 01:27 ET (05:27 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645959000","isCrawlerRequest":true}